Prediction of WHO grade and methylation class of aggressive meningiomas: Extraction of diagnostic information from infrared spectroscopic data

IF 3.7 Q1 CLINICAL NEUROLOGY Neuro-oncology advances Pub Date : 2024-06-06 DOI:10.1093/noajnl/vdae082
R. Galli, Franz Lehner, S. Richter, K. Kirsche, Matthias Meinhardt, Tareq A. Juratli, Achim Temme, M. Kirsch, Rolf Warta, C. Herold-Mende, F. Ricklefs, K. Lamszus, P. Sievers, Felix Sahm, I. Eyüpoglu, Ortrud Uckermann
{"title":"Prediction of WHO grade and methylation class of aggressive meningiomas: Extraction of diagnostic information from infrared spectroscopic data","authors":"R. Galli, Franz Lehner, S. Richter, K. Kirsche, Matthias Meinhardt, Tareq A. Juratli, Achim Temme, M. Kirsch, Rolf Warta, C. Herold-Mende, F. Ricklefs, K. Lamszus, P. Sievers, Felix Sahm, I. Eyüpoglu, Ortrud Uckermann","doi":"10.1093/noajnl/vdae082","DOIUrl":null,"url":null,"abstract":"\n \n \n Infrared (IR) spectroscopy allows intraoperative, optical brain tumor diagnosis. Here, we explored it as a translational technology for the identification of aggressive meningioma types according to both, the WHO CNS grading system and the methylation classes (MC).\n \n \n \n Frozen sections of 47 meningioma were examined by IR spectroscopic imaging and different classification approaches were compared to discern samples according to WHO grade or MC.\n \n \n \n IR spectroscopic differences were more pronounced between WHO grade 2 and 3 than between MC intermediate and MC malignant, although similar spectral ranges were affected. Aggressive types of meningioma exhibited reduced bands of carbohydrates (at 1024 cm-1) and nucleic acids (at 1080 cm-1), along with increased bands of phospholipids (at 1240 and 1450 cm-1). While linear discriminant analysis was able to discern spectra of WHO grade 2 and 3 meningiomas (AUC 0.89), it failed for MC (AUC 0.66). However, neural network classifiers were effective for classification according to both WHO grade (AUC 0.91) and MC (AUC 0.83), resulting in the correct classification of 21/23 meningiomas of the test set.\n \n \n \n IR spectroscopy proved capable of extracting information about the malignancy of meningiomas, not only according to the WHO grade, but also for a diagnostic system based on molecular tumor characteristics. In future clinical use, physicians could assess the goodness of the classification by considering classification probabilities and cross-measurement validation. This might enhance the overall accuracy and clinical utility, reinforcing the potential of IR spectroscopy in advancing precision medicine for meningioma characterization.\n","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology advances","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.1093/noajnl/vdae082","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Infrared (IR) spectroscopy allows intraoperative, optical brain tumor diagnosis. Here, we explored it as a translational technology for the identification of aggressive meningioma types according to both, the WHO CNS grading system and the methylation classes (MC). Frozen sections of 47 meningioma were examined by IR spectroscopic imaging and different classification approaches were compared to discern samples according to WHO grade or MC. IR spectroscopic differences were more pronounced between WHO grade 2 and 3 than between MC intermediate and MC malignant, although similar spectral ranges were affected. Aggressive types of meningioma exhibited reduced bands of carbohydrates (at 1024 cm-1) and nucleic acids (at 1080 cm-1), along with increased bands of phospholipids (at 1240 and 1450 cm-1). While linear discriminant analysis was able to discern spectra of WHO grade 2 and 3 meningiomas (AUC 0.89), it failed for MC (AUC 0.66). However, neural network classifiers were effective for classification according to both WHO grade (AUC 0.91) and MC (AUC 0.83), resulting in the correct classification of 21/23 meningiomas of the test set. IR spectroscopy proved capable of extracting information about the malignancy of meningiomas, not only according to the WHO grade, but also for a diagnostic system based on molecular tumor characteristics. In future clinical use, physicians could assess the goodness of the classification by considering classification probabilities and cross-measurement validation. This might enhance the overall accuracy and clinical utility, reinforcing the potential of IR spectroscopy in advancing precision medicine for meningioma characterization.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
预测侵袭性脑膜瘤的世卫组织分级和甲基化类别:从红外光谱数据中提取诊断信息
红外(IR)光谱可用于术中脑肿瘤的光学诊断。在此,我们根据世界卫生组织中枢神经系统分级系统和甲基化等级(MC),将其作为一种转化技术,用于鉴别侵袭性脑膜瘤类型。 通过红外光谱成像检查了 47 个脑膜瘤的冷冻切片,并比较了不同的分类方法,以根据 WHO 分级或 MC 对样本进行鉴别。 尽管受影响的光谱范围相似,但WHO 2级和3级之间的红外光谱差异比MC中级和MC恶性之间的差异更明显。侵袭性脑膜瘤的碳水化合物(1024 cm-1)和核酸(1080 cm-1)谱带减少,磷脂(1240 和 1450 cm-1)谱带增加。虽然线性判别分析能分辨出 WHO 2 级和 3 级脑膜瘤的光谱(AUC 0.89),但对 MC 却无效(AUC 0.66)。不过,神经网络分类器对 WHO 等级(AUC 0.91)和 MC 等级(AUC 0.83)的分类都很有效,从而对测试集中的 21/23 个脑膜瘤进行了正确分类。 事实证明,红外光谱不仅能根据世界卫生组织的分级提取脑膜瘤的恶性程度,还能提取基于肿瘤分子特征的诊断系统的信息。在未来的临床应用中,医生可以通过考虑分类概率和交叉测量验证来评估分类的准确性。这可能会提高总体准确性和临床实用性,从而加强红外光谱在推进脑膜瘤特征描述精准医疗方面的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.20
自引率
0.00%
发文量
0
审稿时长
12 weeks
期刊最新文献
International symposium on inheritable central nervous system (CNS) cancer predisposition: A prologue. Correction to: Effect of bevacizumab on refractory meningiomas: 3D volumetric growth rate versus response assessment in neuro-oncology criteria. Effect of antibiotic drug use on outcome and therapy-related toxicity in patients with glioblastoma-A retrospective cohort study. Empowering the next generation in neuro-oncology: Introduction of the EANO Career Boost Initiative. A phase 1 dose escalation of pritumumab in patients with refractory or recurrent gliomas or brain metastases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1